Press Release

<< Back

Xenon Pharmaceuticals to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

February 14, 2022

BURNABY, British Columbia, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced its participation in one-on-one investor meetings and a virtual fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference.

Fireside Chat Details:
Thursday, February 17, 2022
5:00-5:30 pm ET
Ian Mortimer, President and CEO

The above listed dates and times are subject to change. Details on company presentations and webcasts can be found on the “Investors” section of Xenon's website at When available, webcasts will be posted for replay following the event.

About Xenon Pharmaceuticals Inc.

We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Investor/Media Contact:
Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353

Primary Logo

Source: Xenon Pharmaceuticals Inc.